Upgrade to SI Premium - Free Trial

Biogen's (BIIB) "P&L Remains Challenged", Focus on CLARITY-AD - BMO Maintains Stock at Market Perform

July 20, 2022 7:53 AM
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $217.00 price target on Biogen (NASDAQ: BIIB), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles